HCM Hutchison China Meditech Ltd Sponsored ADR

HUTCHMED to Announce 2025 Final Results

HUTCHMED to Announce 2025 Final Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).

Both webcasts will be available live via the website of the Company at . The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: or follow us on .

CONTACTS

Investor Enquiries+852 2121 8200 /
  
Media Enquiries 
FTI Consulting –+44 20 3727 1030 /
     Ben Atwell / Tim Stamper     +44 7771 913 902 (Mobile) / 8 (Mobile)
Brunswick – Zhou Yi+852 9783 6894 (Mobile) /
  
Panmure LiberumNominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500
  
CavendishJoint Broker
Geoff Nash / Nigel Birks+44 20 7220 0500
  
Deutsche NumisJoint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith 0


EN
06/02/2026

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

Franc Gregori ... (+2)
  • Franc Gregori
  • Lala Gregorek

Trinity Delta Lighthouse: HUTCHMED

Trinity Delta view: HUTCHMED’s sustainable profitability aim is underpinned by continued commercial and R&D execution. Geographic expansion ex-China, new indications for current China products, and potential new product approvals will support near-term growth, while M&A and/or in-licensing have a role in the mid-term. Accelerated investment in the highly attractive ATTC platform, which could address a wide range of oncology indications with sizeable market potential, should drive longer-term pro...

 PRESS RELEASE

Intended Retirement of Independent Non-executive Director and changes ...

Intended Retirement of Independent Non-executive Director and changes of composition of board committees HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight ...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

HUTCHMED (China) (13 HK): 2025: Results In Line, Sales Recovery To Con...

2025 results were in line. Total revenue declined 13% yoy, but Fruquintinib’s in-market sales rebounded significantly hoh driven by continuous overseas growth and positive impact from sales restructuring in China. It targets oncology/immunology revenue of US$330m-450m supported by continued sales recovery. Seeing smooth R&D progress, we expect a new wave of market approvals to fuel growth for HUTCHMED in the years ahead. Maintain BUY with a lower target price of HK$26.00 reflecting rising geopol...

Bella Lu Yifei ... (+10)
  • Bella Lu Yifei
  • Carol Dou Xiao Qin
  • Claire Wang Kelai
  • Gigi Cheuk
  • Joyce Chu
  • Julia Pan Mengyao
  • Kate Luang
  • Ken Lee
  • Sunny Chen
  • Tham Mun Hon

Greater China Daily: Friday, March 6, 2026

Top Stories Economics | China China set a 2026 GDP growth target of 4.5-5.0% yoy, in line with expectations, while maintaining a 4% fiscal deficit ratio. Fiscal policy remains the main growth driver, supported by Rmb4.4t in local government special bonds and Rmb1.3t in ultra-long treasury bonds, while monetary policy stays accommodative. Policy priorities focus on AI+, New Quality Productive Forces, industrial upgrading, and targeted consumption support, alongside welfare improvements and the g...

 PRESS RELEASE

HUTCHMED Reports 2025 Full Year Results and Business Updates

HUTCHMED Reports 2025 Full Year Results and Business Updates — Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth — — $457 million net income, driven by profitable core operations and non-core disposal — — Rapidly progressing groundbreaking ATTC technology, a source of novel drug candidates with broad therapeutic potential — — Pursuing potential opportunities for partnering ATTC candidates with multinational pharmaceutical companies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J. , March 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Li...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch